Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.
Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin
DRUG: brentuximab vedotin
QTc interval, 2-4 days postdose
ECG parameters, 2-4 days postdose|Blood MMAE levels, Through 4 days postdose|Incidence of proarrhythmic adverse events, Through 1 month following last dose|Incidence of adverse events and laboratory abnormalities, Through 1 month following last dose
The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.